United Therapeutics
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, United Therapeutics sits in the top decile of US sponsors by registered trial count (#328 of 15,742 sponsors by registered trial count).
United Therapeutics: 63 sponsored US clinical trials, 5 recruiting.
United Therapeutics sponsors 63 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 39 completed. 26 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pulmonary Arterial Hypertension, with 4 trials.
Top-decile sponsor footprint
United Therapeutics ranks in the top decile of sponsors by registered trial count (#328 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
39 of 56 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (69.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
63 total, page 1 of 2
Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD
NCT07224763
Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD
NCT06878560
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06388421
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
NCT05776225
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
NCT05203510
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
NCT03045029
Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin
NCT05060315
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
NCT04708782
Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects
NCT04084678
A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD
NCT03857841
Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso
NCT03950739
Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH
NCT03888365
EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension
NCT03497689
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
NCT03626688
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
NCT03794583
A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
NCT03496623
Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF
NCT03043651
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
NCT03037580
Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer
NCT03098030
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
NCT02630316
An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
NCT02633293
Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients
NCT02693171
Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn
NCT02261883
Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension
NCT02279745
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
NCT02276872
Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension
NCT02279160
Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers
NCT02318758
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
NCT01560637
A Pharmacokinetic Substudy of the TDE-PH-304 Protocol
NCT01934582
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
NCT01799473
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
NCT01592045
Three Times Daily Dosing of UT-15C
NCT01746485
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
NCT01560624
Remodulin® to Oral Treprostinil Transition
NCT01588405
Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
NCT01477333
A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension
NCT01028651
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
NCT01266265
A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers
NCT01172496
Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine
NCT01153386
Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities
NCT01165476
The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil
NCT01131845
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
NCT01104870
Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil
NCT00963027
Effect of Food on the Pharmacokinetics of Oral Treprostinil
NCT00963001
Open-Label Study of Oral Treprostinil in Digital Ulcers
NCT00848107
A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients
NCT00969722
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
NCT00887978
Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine
NCT00775463
Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis
NCT00848939
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 14 |
| Phase 3 | 18 |
| Phase 4 | 8 |
What is open in the United Therapeutics pipeline
5 recruiting of 63 indexed (8% open); 39 completed (62%).
Phase mix: 26 late (III/IV) vs 28 early (I/II) (balanced across stages).
Top condition: Pulmonary Arterial Hypertension (4 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
United Therapeutics: open-pipeline peers nationwide
Peers matched on 63 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
United Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 63 trials (± recruiting share)
- Actelion · 63 trials · 0% recruiting
- Hennepin Healthcare Research Institute · 63 trials · 6% recruiting
- University of Oregon · 63 trials · 16% recruiting
- Cephalon · 64 trials · 0% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Novo Nordisk A/S · 8% recruiting · 431 trials
- Arcutis Biotherapeutics · 8% recruiting · 25 trials
- Medtronic Endovascular · 8% recruiting · 25 trials
- Novartis Pharmaceuticals · 8% recruiting · 1,375 trials
Related
What to do with this United Therapeutics page
63 registered trials is a research-attention snapshot, not an endorsement of United Therapeutics or any single study.
- 5 of United Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Pulmonary Arterial Hypertension is the condition United Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pulmonary Arterial Hypertension trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
United Therapeutics pipeline card: 63 registered trials from official public datasets.Report a data error.